The latest announcement is out from Polarean Imaging ( (GB:POLX) ).
Polarean Imaging Plc reported a significant increase in revenue for 2024, driven by a rise in sales of its Xenon gas blend cylinders and consumables, as well as strategic funding from partners. The company is expanding its market presence with new installations and collaborations, including a strategic partnership with SimonMed Imaging to enhance access to its Xenon MRI platform. Polarean is also pursuing international distribution agreements and has secured a new Chinese patent, strengthening its intellectual property portfolio. Despite challenges from changes in NIH funding affecting its primary customers, the company remains confident in achieving its revenue guidance for 2025, supported by a robust pipeline of opportunities and a refined clinical trial plan with the FDA.
More about Polarean Imaging
Polarean Imaging Plc is a commercial-stage medical device company specializing in advanced Magnetic Resonance Imaging (MRI) of lung function. The company focuses on developing and selling proprietary Xenon gas blend cylinders and other consumables, which are used in Xenon MRI scans across clinical and research sites. Polarean is actively expanding its market presence through strategic collaborations and distribution agreements, primarily targeting leading academic medical centers in the United States and exploring opportunities in select international markets.
Average Trading Volume: 1,919,627
Technical Sentiment Signal: Sell
Current Market Cap: £12.37M
See more data about POLX stock on TipRanks’ Stock Analysis page.